Novel panel identifies toxins linked to asthma and GI diseases
Answers from the Lab
Eosinophils are immune-system cells that, when activated, can play a role in a variety of diseases. In this test specific episode of the "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' novel EDN panel goes beyond existing tests to provide relevant information for managing asthma and certain digestive diseases.
Standard testing quantifies eosinophils in blood — but can't determine if those immune cells have been activated and are releasing disease-related neurotoxins. The laboratories' EDN test does exactly that.
"This is the first time we'll have a marker of activation of eosinophils. It's a better way to evaluate patients," Dr. Snyder says. "EDN will be useful for managing treatment and assessing disease activity when there's a suspicion of an eosinophilic component to a patient's disease."
Listen to learn more about Mayo Clinic Laboratories' novel EDN panel.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Collection Instructions: Centrifuge and aliquot serum into a plastic vial within 12 hours of collection. Serum cannot sit on either gel or cells for longer than 12 hours.
Analytic time: 2 to 8 days
Days performed: Tuesday
Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel provides more clinically relevant information for managing adult and pediatric brain tumors.
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.